News Medical media bias and reliability
Ad Fontes Media and Media Bias/Fact Check place News Medical in the centre. We have seen it on 11 published stories of ours.
The short answers
Is News Medical biased?
Ad Fontes Media and Media Bias/Fact Check place News Medical in the centre. An outlet rating describes a broad pattern in its output, not every article it publishes.
Is News Medical left or right?
Ad Fontes Media and Media Bias/Fact Check place News Medical in the centre. In the three-way grouping used on story pages, that puts it under Centre.
Is News Medical reliable?
The factual-reliability assessments we hold for News Medical are Ad Fontes Media: Very high factuality; Media Bias/Fact Check: High factuality. These are outlet-level assessments, not a guarantee that every report is correct.
What News Medical has been covering
Our account of each story, written from every outlet that ran it, with News Medical’s own report linked underneath.
AstraZeneca has released full results from two late-stage trials of its experimental COPD drug, tozorakimab. The data indicates the drug reduced flare-ups by up to 43% in various patient groups and has led AstraZeneca to raise its peak annual sales forecast for the drug to over $5 billion.
News Medical reported it asNew biologic therapy significantly reduces COPD flare-ups in trials (opens News Medical in a new tab)
A study examining UK medical records found that semaglutide, the active ingredient in Ozempic and Wegovy, was associated with a nearly 40% reduction in asthma attacks and a 20% decrease in COPD flare-ups. Scientists suggest anti-inflammatory properties may be responsible, but caution that further trials are needed.
News Medical reported it asGLP-1 treatment linked to 40% fewer asthma attacks (opens News Medical in a new tab)
Insilico Medicine's AI-designed drug rentosertib, tested in a small study for idiopathic pulmonary fibrosis, indicated a reduction in biological age markers. Six independent aging clocks suggested patients treated with the drug appeared biologically younger than those on placebo, with the largest effect seen in the 30mg twice-daily arm.
News Medical reported it asAI-designed drug candidate reverses biological age in clinical study (opens News Medical in a new tab)
A genetically modified pig kidney functioned in a human patient for a record 271 days, allowing the individual to avoid dialysis while awaiting a human transplant. The results were published in The Lancet by doctors from Massachusetts General Hospital and Harvard Medical School.
News Medical reported it asPig kidney xenotransplantation offers a bridge for patients awaiting human donor kidneys (opens News Medical in a new tab)
Alcohol-attributable cancer deaths in the United States more than doubled between 1990 and 2023, rising from 11,361 to 23,126. The increased risk applies to multiple cancer types, including breast, colorectal, and head and neck cancers.
News Medical reported it asAlcohol-linked cancer deaths doubled over three decades in America (opens News Medical in a new tab)
An artificial intelligence tool developed at Imperial College London analyses electrocardiograms in under two seconds to identify signs of heart failure and valve disease. The system, trained on millions of ECGs, detected up to 81% of heart failure cases and 90% of valve disease cases in a US study of 67,000 patients.
News Medical reported it asECG-CLIP improves heart disease detection using less labeled data (opens News Medical in a new tab)
Research indicates the Shingrix vaccine may provide protection against cardiovascular events and dementia. A study found a reduced risk of heart disease and cognitive decline in those vaccinated compared to an older vaccine.
News Medical reported it asThe US switch in shingles vaccines revealed an unexpected heart health pattern (opens News Medical in a new tab)
The U.S. Food and Drug Administration has approved daraxonrasib, branded as Rasonque, for metastatic pancreatic cancer. In trials, patients taking the drug lived a median of 13.2 months, compared to 6.7 months on chemotherapy.
News Medical reported it asFDA approves first RAS-targeted therapy for metastatic pancreatic cancer (opens News Medical in a new tab)
Higher levels of the popular sugar substitute xylitol have been associated with a significantly greater risk of heart attack and stroke, according to new research. The analysis examined data from over 17,000 individuals, finding those with xylitol in their blood were at increased risk of major cardiovascular events.
News Medical reported it asArtificial sweetener xylitol associated with higher risk of adverse cardiovascular events (opens News Medical in a new tab)
A major review of 80 randomized controlled trials found that nicotine e-cigarettes were more effective than nicotine replacement therapy for helping people quit smoking. The review involved nearly 30,000 participants and found no evidence of increased serious harm from using e-cigarettes to quit.
News Medical reported it asNicotine e-cigarettes help more smokers quit than conventional methods (opens News Medical in a new tab)
Scientists at the Arc Institute in California used an AI model named Evo to design 16 new bacteriophages capable of infecting E. coli. The study, published in Science, excluded human pathogen datasets, ensuring the viruses cannot infect people. Experts warn of biosecurity risks despite potential medical applications.
News Medical reported it asResearchers use AI to design functional bacteriophage genomes from scratch (opens News Medical in a new tab)
Who says so
2 organisations have published a rating for this outlet, in their own words. Where they disagree, the disagreement is the useful part and it is left standing.
How reliably it reports fact
A rating of the newsroom in general, by others, and a different thing from the Trust score we publish on each story, which judges one piece of reporting.
High factuality
Who owns it
- AZoM.com Limitedunknowndirect owner
- AZoNetworkunknownparent group
- Ian Birkbyunknownparent group
Where it publishes from
- Publishes from
- Mona Vale, Northern Beaches Council, New South Wales, Australia
- Official site
- news-medical.net
- Seen publishing on
- news-medical.net
- Access
- Free to read
What we have seen ourselves
Counted across the stories this site has published, which is the only denominator a reader can check: every one of them has a page, and every page lists the reports it was written from.
- Stories
- 11
- Reports listed
- 11
- We could read
- 3
- First seen
- 4 August 2026
8 of those reports were paywalled or blocked to us. Our reading of this outlet is built on the 3 we could open, not on everything it published.
A blindspot is measured against one side of the spectrum. News Medical is rated centre, so there is no side for it to be counted against and we publish no figure here.
Across the 11 stories of ours where at least three of the reports we listed carried a time, another outlet was always ahead of News Medical: its report arrived a median of 16 hours after the earliest one we logged.
Measured 19 September 2026. Last seen in a coverage list 14 September 2026. Ratings pulled 4 September 2026.
Other outlets rated the same way
Publishers carrying the same published leaning as News Medical, also publishing from Australia, ordered by how often we have seen them on a story. Sharing a rating is not the same as being alike.
Think this page is wrong?
The leanings above are published by AllSides, Ad Fontes Media and Media Bias/Fact Check, and we republish them rather than make them. If you think one is misapplied, the strongest place to say so is with the organisation that made it, and every verdict here links to their page.
What we are responsible for is everything else: the ownership chain, where News Medical publishes from, which of our stories we have listed it on, and whether we have the right publisher at all. Tell us what is wrong and an editor reads it.
Report something wrong on this page
Anything we correct is written up in the public corrections log. We do not publish reader votes as a rating, because an unattributed rating is the thing this site exists to argue against.
Every rating on this page is a named third party’s published work, republished with its author and, where one exists, a link to it. Our own coverage record is the section we measure ourselves. Neither is a judgement of any individual report: those are scored story by story, and the reasoning is on our methodology page.